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Abstract
Objective: The aim of the study was to evaluate the association of individual and com­
bined single-nucleotide polymorphisms in brain-derived neurotrophic factor (BDNF), 
dopamine transporter (DAT), and catechol-O-methyltransferase (COMT) genes with 
the occurrence of motor levodopa-induced complications (MLIC) in Parkinson's dis­
ease (PD).
Materials and Methods: We studied 76 patients with PD (MLIC occurred in 56.6%) 
and 60 controls. Allelic discrimination of rs6265 BDNF (Val66Met), rs397595 DAT 
(SLC6A3), and rs4680 COMT (Val158Met) genes were genotyped. Odds ratios (OR) 
and 95% confidence intervals (95% CI) were calculated using multinominal logistic 
regression. Orthogonal partial least squares (OPLS) analysis and OPLS discriminant 
analysis (OPLS-DA) were used to analyze qualitative genetic data.
Results: The risk of PD in subjects with the AG BDNF genotype was increased sixfold 
(OR = 6.12, 95% CI = 2.88-13.02, p < .0001), and AG BDNF and AG DAT genotypes 
were correlated with PD in OPLS-DA (VIP > 1). There were no differences in distri­
butions of BDNF, DAT and COMT genotypes between PD groups with and without 
MLIC, while OPLS model showed that genotype combination of AG BDNF, AG DAT, 
and GG COMT was correlated with MLIC and genotypes combination of GG BDNF, 
AA DAT, and AA COMT with lack of MLIC in PD patients (VIP > 1).
Conclusions: Our results confirmed the association of rs6265 BDNF (Val66Met) with 
the risk of PD and suggest a synergic effect of rs6265 BDNF (Val66Met), rs397595 
DAT (SLC6A3), and rs4680 COMT (Val158Met) polymorphisms on the occurrence of 
MLIC.
K E Y W O R D S
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1 | IN T R O D U C T IO N
Chronic dopaminergic therapy of Parkinson's disease (PD) is asso­
ciated with a risk of motor levodopa-induced complications (MLIC): 
motor fluctuations and dyskinesias. The inter-individual heterogeneity 
in their development suggests a complex pathomechanism involving 
also genetic factors. Previous studies about genetic associations be­
tween M LIC and its pathophysiological mechanism reported however 
inconsistent results. The brain-derived neurotrophic factor (B D N F) is 
thought to modulate synaptic transmission and plasticity and to me­
diate in neuronal survival, migration and differentiation in many re­
gions of the brain, including on dopaminergic nigrostriatal neurons. 
Functional consequences of a common Val66M et single-nucleotide 
polymorphism (SNP) of the B D N F  gene (rs6265) involve decreased 
protein secretion in carriers of A  (Met) allelic variants (Egan et al., 
2003). That SN P has seemed to influence the dyskinesias onset in 
the course of PD treatment with dopaminergic agents (Foltynie et al., 
2009). However, more recent studies did not evidence any association 
between several SN Ps of the B D N F  gene, including Val66M et, and the 
risk of developing levodopa-induced dyskinesias (Cheshire et al., 2014; 
Kaplan et al., 2014). The dopamine transporter (DAT), a plasma mem­
brane protein of dopaminergic neurons, plays an important role in con­
trolling the intensity and duration of dopaminergic neurotransmission 
by rapid DA reuptake into presynaptic terminals. It was demonstrated 
that motor fluctuations in PD are associated with rapid increase in the 
synaptic levels of DA probably due to increased D A  turnover related 
to lower DAT levels in nigrostriatal neurons (Fuente-Fernandez et al., 
2001; Sossi et al., 2007). Two variations of the DAT gene, which func­
tional effects are still unclear, seem to be correlated with levodopa-in­
duced dyskinesias in PD: the rs393795 SN P  (Kaplan et al., 2014) and 
the 40-base-pair (pb) variable number tandem repeat (V N TR) polymor­
phism (Kaiser et al., 2003). Catechol-O-m ethyltransferase (CO M T) and 
monoamine oxidases (MAO) are involved in the metabolism of amine 
neurotransmitters and play a central role in therapeutic response to 
levodopa. The allele A  (Met) of a common SN P in the C O M T gene, the 
Val158M et (rs4680), is linked to increased thermolability and reduced 
activity of the enzyme (Lotta et al., 1995). On the one hand, the suscep­
tibility to M LIC  was reported to be influenced by this polymorphism 
in C O M T gene (Hao et al., 2014; de Lau, Verbaan, Marinus, Heutink, 
& Hilten, 2012; W atanabe et al., 2003; W u et al., 2014), and on the 
other hand, no associations between C O M T Val158M et and T941G 
M A O -A  SN Ps either individually or combined and levodopa-induced 
dyskinesias were found (Cheshire et al., 2014). The aim of the study 
was to evaluate the association of individual and combined SN Ps in 
rs6265 B D N F  (Val66Met), rs397595 DAT (SLC6A3), and rs4680 C O M T 
(Val158Met) genes with the occurrence of M LIC in PD  patients.
2 | M A T E R IA LS  A N D  M E T H O D S
2.1 | Subjects
The inclusion of patients with idiopathic PD  into the study was 
based on the clinical diagnosis of the disease according to the U K
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PD S Brain Bank criteria and the E F N S /M D S -E S  recom m endations, 
and chronic levodopa therapy lasting at least 3 years. Seven ty-six  
patients have been included to the PD group and 60 to the co n­
trol group. PD  patients were treated as follows: (a) levodopa and 
ropinirole—33 patients (43.4%), (b) levodopa m onotherapy—19 
patients (25%), (c) levodopa and piribedil 7 5 -1 5 0  mg daily (mean 
109.36 mg daily)—eight patients (10.5%), (d) levodopa and ropin- 
irole and entacapone—six patients (7.9%), (e) levodopa and ropin- 
irole and am antadine—three patients (4%), (f) levodopa and piribedil 
(150 mg daily) and am antadine— 3 patients (4%), (g) levodopa and 
am antadine—two patients (2.6%), (h) levodopa and entacapone 
and am antadine—one patient (1.3%), (i) levodopa and ropinirole 
and entacapone and am antadine—one patient (1.3%). The  levo­
dopa equivalent dose (LED) was calculated (Tom linson et al., 2010). 
Am ong 60  controls, 28 had mild ischem ic stroke, 21—transient is­
chem ic attack, four—posttraum atic subdural hematoma non requir­
ing surgical intervention, tw o —discopathy, tw o—unruptured brain 
aneurysm , one—normal pressure hydrocephalus, one—epilepsy and 
one—tension-type headache. The  progression of PD  was evaluated 
using Hoehn and Yahr scale, the motor sym ptom s severity—using 
the Unified Parkinson's D isease Rating Scale (U PD R S) part III (in ON 
phase) and com plications of therapy—using U P D R S  IV ([A] d ysk i­
nesias, [B] clinical fluctuations, and [C] other com plications) or: (IV 
A  - dyskinesias, IV  B - clinical fluctuations, and IV C  - other com ­
plications). The  study protocol was approved by the relevant local 
B ioethics Com m ittee and conform ed to the standard set by the 
Declaration of Helsinki. A ll participants gave their inform ed co n­
sent prior to their inclusion in the study.
The baseline characteristics of the groups were presented in 
Table 1. There was no difference in sex between the PD  group and 
controls. PD  patients were younger than controls, and men were 
younger than women in both PD and control group. There were no 
differences in PD  duration, daily dose of levodopa and ropinirole, LED, 
duration of levodopa and ropinirole treatment, U P D R S III and Hoehn 
and Yahr scale scores between male and female in the PD  group. 
Male PD  patients were younger at disease onset than female. M LIC 
occurred in 43 (56.6%) PD  patients (24 female, 19 male) with mean 
duration of 3.24 (range 0 .5 -8 ) years and after on average 6.16 years 
of dopaminergic treatment. There were 16 (37.2%) patients with only 
on-off phenomena, and 27 (62.8%) with both on-off phenomena and 
dyskinesias.
2.2 | Genetic analysis
Genom ic D N A  was isolated from peripheral blood sam ples using 
G e n e JE T  blood genom ic D N A  purification kit (Therm o Fisher 
Scientific) follow ing the m anufacture's recommended protocol. D N A  
concentrations were determined using the NanoDrop 20 0 0  U V/VIS 
spectrophotom eter (Therm o Fisher Scientific). A llelic discrim ina­
tion of the rs6265 B D N F  (Val66M et), rs397595 D A T (SLC6A3), and 
rs4680  C O M T  (Val158M et) gene variants were genotyped by using 
pre-validated allelic discrim ination TaqM an Real-Tim e P C R  A ssay 
(Applied Biosystem s).
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T A B L E  1 Parkinson's disease patients 
and controls baseline characteristics
Number of patients 76 60
_Brain and Behavior  W l  ^ 3 °f 11
p value
PD patients Control group PD versus controls
Sex
Female 40 29 nsa
Male 36 31
Age (years)
mean ± standard deviation (range)
All 65.7 ± 9.4 (41-79) 70.5 ± 12.0 (51-88) .01
Female 68.4 ± 9.0 73.6 ± 10.1
Male 62.6 ± 8.9 66.9 ± 12.5
p value <.01 <.01
Female versus Male
Age at PD onset (years)
mean ± standard deviation (range)
All 55.4 ± 8.9 (32-72)
Female 57.6 ± 8.3
Male 52.9 ± 8.9
p value <.05
Female versus Male
Duration of PD (years) 10.3 ± 4.6
mean ± standard deviation (3-23)
(range)
Dose of levodopa (mg/daily) 812.5 ± 381.6
mean ± standard deviation (200-2,550)
(range)
Duration of levodopa 8.6 ± 4.4
treatment (years) (1-20)
mean ± standard deviation
(range)
Dose of ropinirole (mg/daily) 3.3 ± 3.4
mean ± standard deviation (0-12)
(range)
Duration of ropinirole 2.4 ± 2.8
treatment (years) (0-12)
mean ± standard deviation
(range)
Levodopa equivalent dose 871.8 ± 385.3
(mg/daily) (200-2,550)
mean ± standard deviation 
(range)
UPDRS III score 18.9 ± 9.6
mean ± standard deviation (3-43)
(range)
Hoehn and Yahr scale score 2.7 ± 0.7
mean ± standard deviation (1.5-4.0)
(range)
Abbreviations: ns, nonsignificant; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease 
Rating Scale.
aFisher's exact test, 2 x 2 contingency table, nothing—Student's t test.
2.3 | Statistical analysis followed by Yates correction test (Statistica v. 10, StatSoft, Inc., www.
statsoft.com ). The chi-square test was used to analyze frequencies 
Statistical analysis was performed using Student's t test, M ann- of the genotypes for deviations from Hardy-W einberg equilibrium
W hitney test, Fisher's exact test, and contingency table chi-square (H W E) in PD  patients, controls, and PD patients with and without
M LIC. Testing deviation from the H W E, Pearson's chi-squared test, 
or Fisher's exact test was used to observed genotype frequencies 
obtained from the data and the expected genotype frequencies ob­
tained using the H W E. Odds ratios (OR) and 95% confidence inter­
vals (95% CI) were calculated using multinominal logistic regression 
(SPSS v.13). The differences were considered significant if the p value 
was >.05. Multivariate projection methods for data exploration—or­
thogonal partial least squares (O PLS) analysis and O P LS  discriminant 
analysis (O P LS -D A )—were used to analyze qualitative genetic data. 
The quality of O P LS /O P LS -D A  model was described by two param­
eters: goodness of fit (R2cum) and goodness of prediction reported 
as the cumulative score across all of the components (Q2cum). Model 
was considered as good when R2cum and Q2cum values were equal or 
greater than 0.5. The variable importance in the projection (VIP) value 
for model was calculated to indicate their contribution to the clas­
sification. Variables with V IP  value >1.0 were considered significantly 
different. The model was validated using the analysis of variance test­
ing of cross-validated predictive residuals (CV -A N O V A). Multivariate 
analysis (O P LS/O P LS-D A ) was performed using the S IM C A -P  soft­
ware package (Version 14, Umetrics AB).
3 | R E SU LT S  
3.1 | Genotype distributions of rs6265 BDNF, 
rs397595 DAT, and rs4680 COMT polymorphisms in 
PD patients and controls
G enotype d istributions of B D N F, DAT, and C O M T  polym orphism s 
with O R  and 95% CI in PD  patients and controls have been shown 
in Table 2. Both groups were in H W E concerning D A T and C O M T 
genotypes (p > .05). The distribution of B D N F  genotypes did not 
show sign ificant deviation from H W E in the controls (p > .05); how ­
ever, B D N F  polym orphism  did not d isp lay H W E in the PD  group 
(p < .0001). A  higher frequency of A G  B D N F  genotype was seen in 
PD  patients (67.1%) and of GG B D N F  genotype in controls (73.3%). 
Sex did not have influence on distribution of these genotypes both 
in PD  patients and controls. The multinominal logistic regression 
analysis showed sign ificant d ifferences in the distribution of B D N F  
genotypes (p < .0001) and no d ifferences in d istributions of DAT 
and C O M T  genotypes between PD  patients and controls. The  risk 
of PD  in subjects with the A G  B D N F  genotype was increased sixfold 
(O R  = 6.12, 95% CI = 2 .8 8 -1 3 .0 2 , p < .0001). No such association 
was observed with G G  and A A  hom ozygotes, although the low fre­
q uency of A A  genotype and small sample size should be noted.
3.2 | OPLS-DA of genotypes in PD 
patients and controls
O rthogonal partial least squares-discrim inant analysis indicated that 
it was possible to differentiate PD  patients and controls based on 
genetic data. Model consisted of one predictive com ponent, two
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orthogonal com ponents, and one com ponent unrelated to genes 
and groups. The model was described by cum ulative variation 
(R2cum = 0.776, Q2cum = 0.111) and was validated using C V -A N O V A  
(p = .02). The  m ost im portant genotypes involved in groups d ifferen­
tiation were as follows: AG  B D N F, GG B D N F, and A A  D A T (V IP  > 1). 
A G  B D N F  and AG  D A T were correlated with PD  while GG B D N F  and 
A A  D A T with controls (Figure 1a,b).
3.3 | Clinical comparison between Parkinson's 
disease patients with and without MLIC
Clinical differences between PD  patients with and without M LIC were 
presented in Table 2. Patients with M LIC were younger, developed PD 
earlier and had more advanced PD  stage in Hoehn and Yahr scale in 
comparison with patients without M LIC. Those differences in age and 
age at disease onset were observed in male but not in female PD pa­
tients, whereas higher score in Hoehn and Yahr scale affected female 
but not male PD patients. Patients with M LIC (female and male) took 
higher daily levodopa dose and LED  and were treated with levodopa 
longer in comparison with patients without M LIC. There was no dif­
ference in sex, mean duration of PD, daily dose of ropinirole, duration 
of ropinirole treatment, and U PD RS III and IVC score between those 
groups. Statistical analysis indicated no clinical differences between 
patients with only on-off phenomena and patients with both on-off 
phenomena and dyskinesias (except for scores in U P D RS IV  A  and B 
rating dyskinesias and clinical fluctuations; Table 3).
3.4 | Genotype distributions and OPLS analysis of 
rs6265 BDNF, rs397595 DAT, and rs4680 COMT 
polymorphisms in PD patients with and without MLIC
Genotype distributions of BDN F, DAT, and C O M T polymorphisms 
with O R  and 95% CI in PD  patients with and without M LIC  were shown 
in Table 4. The frequencies of DAT and C O M T genotypes displayed 
H W E in both PD  groups (p > .05) while the distribution of B D N F  geno­
types showed significant deviation from H W E also in both PD  groups 
(p = .001 and p = .009, respectively) (Table 4) and in M LIC subgroups 
(patients with only on-off phenomena and patients with both on-off 
phenomena and dyskinesias: p = .016 and p = .018, respectively) as 
well. The multinominal logistic regression analysis showed no differ­
ences in distributions of BDN F, DAT, and C O M T genotypes between 
PD  groups without and with M LIC  as well as between M LIC  subgroups 
(p > .05), and sex did not influence those distributions. O P LS  analysis 
demonstrated that it was possible to differentiate PD  groups with and 
without M LIC  upon gene analysis. Model consisted of two predictive 
components and one orthogonal component. The model was de­
scribed by cumulative variation (R2cum = 0.834, Q2cum = 0.678) and 
was validated using C V -A N O V A  (p < .0001). The m ost im portant gen­
otypes involved in groups differentiation were as follows: AG  BDNF, 
A G  DAT, and A A  D A T (V IP  > 1). Genotype combination of AG  BDNF, 
A G  DAT, and GG C O M T was correlated with PD  patients with M LIC
T A B L E  2 G enotype frequencies of rs6265 B D N F  (Val66M et), rs397595 D A T (SLC6A3) and rs4680 C O M T  (Val158M et) polym orphism s in 
Parkinson's disease patients and controls
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PD patients Controls x 2 p value p value
Gene Genotypes n (%) n (%) PD/controls PD/controls O R  (95% CI) PD versus controls
BDNF All GG 24 (31.6%) 44 (73.3%) 17.322/0.047 <.0001/.828 0.17 (0.08-0.36) <.0001
AG 51 (67.1%) 15 (25.0%) 6.12 (2.88-13.02) <.0001
AA 1 (1.3%) 1 (1.7%) 0.79 (0.05-12.84) 1.0
Female GG 14 (35.0%) 21 (72.4%) 9.273/0.183 .002/.669 0.21 (0.07-0.58) .005
AG 26 (65.0%) 7 (24.1%) 5.84 (2.0-17.02) .002
A A 0 (0%) 1 (3.5%) 0 -
Male GG 10 (27.8%) 23 (74.2%) 8.346/0.680 .004/.410 0.13 (0.05-0.40) .0004
AG 25 (69.4%) 8 (25.8%) 6.53 (2.23-19.1) .0009
AA 1 (2.8%) 0 (0%) 0 -
DAT All AA 38 (50.0%) 39 (65.0%) 3.726/0.234 .054/.628 0.54 (0.27-1.08) .11
AG 36 (47.4%) 18 (30.0%) 2.1 (1.03-4.28) .04
GG 2 (2.6%) 3 (5.0%) 0.51 (0.08-3.18) .65
Female AA 20 (50.0%) 20 (69.0%) 2.0575/3.961 .151/.047 0.45 (0.17-1.23) .18
AG 19 (47.5%) 6 (20.7%) 3.47 (1.16-10.34) .04
GG 1 (2.5%) 3 (10.3%) 0.22 (0.02-2.25) .3
Male AA 18 (50.0%) 19 (61.3%) 1.672/1.786 .196/.181 0.63 (0.24-1.67) .5
AG 17 (47.2%) 12 (38.7%) 1.42 (0.53-3.76) .65
GG 1 (2.8%) 0 (0%) - -
COM T All AA 28 (36.8%) 21 (35.0%) 1.599/1.769 .206/.183 1.08 (0.53-2.2) 1.0
AG 34 (44.7%) 28 (46.7%) 0.93 (0.47-1.83) 1.0
GG 14 (18.4%) 11 (18.3%) 1.0 (0.42-2.41) .8
Female AA 20 (50.0%) 20 (69.0%) 2.0575/3.961 .151/.047 0.45 (0.17-1.23) .18
AG 19 (47.5%) 6 (20.7%) 3.47 (1.16-10.34) .04
GG 1 (2.5%) 3 (10.3%) 0.22 (0.02-2.25) .3
Male AA 18 (50.0%) 8 (25.8%) 0.252/0.034 .616/.853 2.88 (1.02-8.1) .04
AG 14 (38.9%) 16 (51.6%) 0.6 (0.23-1.58) .4
GG 4 (11.1%) 7 (22.6%) 0.43 (0.11-1.63) .4
Abbreviations: 95% CI, 95% confidence interval; BDNF, brain-derived neurotrophic factor; COMT, catechol-O-methyltransferase; DAT, dopamine 
transporter; OR, odds ratio; PD, Parkinson's disease;x 2, chi-square.
and genotype combination of GG BD N F, A A  DAT, and A A  C O M T with 
PD patients without M LIC  (Figure 1c,d).
4 | D IS C U S S IO N
From years, B D N F  gene has been considered to be a potential candi­
date for susceptibility to PD  due to decreased B D N F  m RN A  expression 
and protein content observed in substantia nigra of PD  patients (Mogi 
et al., 1999). In the present study conducted on Polish Caucasians sub­
jects, PD patients were significantly more frequently carriers of the 
heterozygous AG  allele of B D N F  Val66M et polymorphism and con­
trols were significantly more frequently carriers of the homozygous 
GG allele. The multinominal logistic regression analysis demonstrated 
the sixfold increased risk of PD  in carriers of the A G  B D N F  genotype. 
No such association was observed for A A  hom ozygotes probably due
to the low frequency of hom ozygous genotype and small samples size. 
The presence of the allele A  led to lower activ ity  dependent secretion 
of the protein; therefore, heterozygotes AG  also showed impaired 
intracellular distribution and lower secretion levels of BDN F, even 
though presumably not as pronounced as hom ozygotes A A  (Egan et 
al., 2003). The association between B D N F  Val66M et polymorphism 
and susceptibility to PD was previously investigated with inconsist­
ent results. There was no association found between that S N P  and 
the risk of developing PD  independently of the ethnicity in several 
m eta-analysis (Dai et al., 2013; Mariani et al., 2015) except for one 
that identified an association between that SN P  and PD in Europeans 
but not in Asians (Lee & Song, 2014). Other SN Ps of the B D N F  gene 
were investigated, and a relationship between B D N F  712A /G  A G /A A  
genotypes and PD  was suggested in Chinese Han population (Chen et 
al., 2011). O ur data support the hypothesis that the insufficient sup­
ply of B D N F  may contribute to the neurodegenerative process in PD.
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F I G U R E  1 O P L S /O P L S -D A  analysis of rs6265 B D N F  (Val66M et), rs397595 D A T (SLC6A 3), and rs4680  C O M T  (Val158M et) 
polym orphism s in Parkinson's disease patients versus controls (a, b) and in Parkinson's disease patients with versus without motor levodopa- 
induced com plications (c, d). (a) O rthogonal partial least squares-discrim inant analysis (O P LS -D A ) scores plot of Parkinson's disease (PD) 
patients and control genetic data showing separation between both groups. The score vector to[1] represents w ithin-group variation in 
the orthogonal com ponent, while the score vector t[1] represents between-group variation in the predictive com ponent, Num —number of 
sample. (b) score contribution of genetic data to group differentiation. (c) orthogonal partial least squares-discrim inant analysis (O PLS) scores 
plot of two Parkinson's disease (PD) groups (M LIC(+)—with motor levodopa-induced com plications and M LIC (-)—w ithout motor levodopa- 
induced complications) genetic data show ing separation between both groups. The score vector t[1] represents first com ponent, while the 
score vector t[2] represents second com ponent, N um —number of sample. (d) score contribution of genetic data to group differentiation. 
BD N F, brain-derived neurotrophic factor; CO M T, catechol-O -m ethyltransferase; DAT, dopamine transporter
W e did not evidence associations betw een individual DAT 
(rs397595) and C O M T  V a l158M et polym orphism s and PD  but 
O P L S -D A  m odel show ed that genotype com bination of AG  B D N F  
and AG  D A T w as correlated with PD  patients and genotype com ­
bination of G G  B D N F  and A A  D A T with controls. Th e  link between 
D A T polym orphism s and su scep tib ility  to PD  m ight co n sist in 
changes in D A T expression and synap tic  uptake of potential neu­
rotoxins responsib le for nigral cell death (T ipton & Singer, 1993). 
Am ong Japanese PD  patients, no evidence of association between 
the 1 215A /G  polym orphism  in D A T gene and PD  was found in 
one stu d y (Kim ura, M atsushita, Arai, Takeda, & H iguch i, 2001), 
while such association w as confirm ed in two others (M orino et 
al., 2 0 0 0 ; N ishim ura, Kaji, O hta, M izuta, & Kuno, 2002) and the 
10-co py genotype of 4 0 -p b  V N T R  polym orphism  in that gene was 
suggested to make a protective  factor for the developm ent of PD 
in male Taiw anese (Lin et al., 2003). G enetic variations in C O M T  
gene w ere proposed as a suscep tib ility  factor for PD  because of 
their role in the inactivation of m any b io logica lly  active  and toxic 
catechols. The  allele A  of the C O M T  V a l158M et polym orphism  
is linked to low (L) C O M T  a ctiv ity  of the enzym e, in co ntrast to 
the allele G linked to high (H) C O M T  a ct iv ity  (Lotta et al., 1995) 
and the C O M T  enzym atic a ct iv ity  in women is low er than in men
(Xie, Ho, & Ram sden, 1999). Th e  involvem ent of C O M T  V al158M et 
S N P  in the suscep tib ility  of PD  w as detected in A sian  populations 
(Chuan et al., 2015; K iyohara et al., 2011) and of C O M T  V al108M et 
S N P  (L/L  genotype) in younger sub jects and in women am ong US 
patients with both parents of European origin (Goudreau et al.,
2002). M eta-analysis show ed both no association betw een C O M T 
V a l108/158M et S N P  and PD  regardless of e th n icity  (Jim enez- 
Jim enez, A lo n so -N avarro , G arcia-M artin , & A gu n d ez, 2014) and 
association of C O M T  V a l158M et PSN  and the risk of PD  in A sians 
rather than C au casian s (Lechun, Yu, Pengling, & C an ggi, 2013). 
Th at risk w as found with the C O M T  H /L  genotype of V al108M et 
S N P  in interaction with the M A O -B  G genotype of polym orphism  
of intron 13 in fem ale PD  patients in Polish population (B iałecka 
et al., 2005). The  e th n icity  rem ains c learly  a key fa cto r for genetic 
susceptib ilities in PD  and considering not on ly single polym or­
phism s but also overlapping e ffe cts  of more than one seem s to be 
appropriate.
Motor levodopa-induced com plications (there were in the major­
ity patients with both on-off phenomena and dyskinesias) occurred 
in 56.6%  of PD  patients (55.8% females) and were associated with 
younger age and younger age at PD  onset (in men), more increased 
disease severity (in women), higher daily levodopa dose and LED
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T A  B L E  3 Clinical d ifferences between Parkinson's disease patients with and w ithout motor levodopa-induced com plications
PD patients with M LIC
All
W ith only 
on-off
W ith both 
on-off and 
dyskinesias
p value
PD patients with 
only on-off versus 
with both on-off 
and dyskinesias
PD patients 
without M LIC
p value
PD patients with 
M LIC versus 
without M LIC
Number (percentage) of 
patients
43 (56.6%) 16 (37.2%) 27 (60.4%) - 33 (43.4%) -
Sex
Females
number (percentage)
24 (55.8%) 8 (50%) 16 (59.3%) nsa 16 (44.2%) nsa
Males
number (percentage)
19 (44.2%) 8 (50%) 11 (40.7%) 17 (55.8%)
Age (years) 
mean i  standard 
deviation (range)
All 63.4 i  9.2 (41-79) 61.8 i  7.8 64 i  10 ns 68.6 i  8.8 (51-88) .017
Female 66.4 ± 10.4 60.9 i  9.4 67.3 i  8.9 ns 67.9 ± 8.8 ns
Male 60.9 ± 8.4 62.6 i  6.3 59.3 i  10.0 ns 68.5 ± 8.3 .011
p value
Female versus Male
ns ns ns ns
Age at PD onset (years) 
mean ± standard 
deviation (range)
All 52.7 i  8.3 
(32-69)
51.9 i  7.9 53.0 i  8.6 ns 58.8 i  8.5 (39-72) .003
Female 54.2 ± 9.6 51.6 i  10.8 55.5 i  7.8 ns 58.8 i  7.3 ns
Male 50.0 i  7.5 52.3 i  3.9 49.3 i  8.8 ns 59.5 i  8.1 .001
p value
Female versus Male
ns ns ns ns
Duration of PD (years) 
mean ± standard 
deviation (range)
10.7 i  4.1 
(4-20)
9.8 i  3.9 
(4-18)
11.0 i  4.2 
(5-20)
ns 9.8 i  5.1 
(3-23)
ns
Dose of levodopa (mg/ 
daily) 
mean ± standard 
deviation (range)
944.2 i  406.2 
(200-2,550)
932.2 i  262.5 
(600-1,455)
975.0 i  475.8 
(200-2,550)
ns 640.9 i  266.5 
(200-1,250)
<.001
Duration of levodopa 
treatment (years) 
mean ± standard 
deviation (range)
9.4 i  4.2 
(1-20)
8.4 i  4.0 
(3-16)
9.7 i  4.3 
(1-20)
ns 7.6 i  4.3 
(1-20)
.025
Dose of ropinirole (mg/ 
daily) 
mean ± standard 
deviation (range)
3.3 i  3.4 
(0-12)
3.6 i  3.7 
(0-12)
3.3 i  3.4 
(0-9)
ns 3.2 i  3.3 
(0-10)
ns
Duration of ropinirole 
treatment (years) 
mean ± standard 
deviation (range)
2.1 i  2.4 
(0-10)
2.2 i  2.5 
(0-8)
2.3 i  2.6 
(0-10)
ns 2.7 i  3.3 
(0-12)
ns
Levodopa equivalent 
dose (mg/daily) 
mean ± standard 
deviation (range)
1,008.0 i  395.6 
(200-2,550)
932.2 i  262.5 
(600-1,455)
965.4 i  476.5 
(200-2,250)
ns 694.3 i  291.9 
(215-1,360)
<.001
(Continues)
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PD patients with M LIC
W ith only 
All on-off
W ith both 
on-off and 
dyskinesias
p value
PD patients with 
only on-off versus 
with both on-off 
and dyskinesias
PD patients 
without M LIC
p value
PD patients with 
M LIC versus 
without M LIC
UPDRS III score 
mean i  standard 
deviation (range)
18.4 i  9.5 
(4-40)
19.4 i  10.8 
(0-35)
16.9 i  8.8 
(4-38)
ns 19.7 i  9.8 
(3-43)
ns
UPDRS IV A  score 
mean i  standard 
deviation (range)
2.3 i  2.4 
(0-9)
0 3.5 i  2.2 
(1-9)
<.001 0 <.001
UPDRS IV B score 
mean i  standard 
deviation (range)
3.2 i  1.0 
(1-5)
2.5 i  1.1 
(0-4)
3.4 i  0.9 
(2-5)
.012 0 <.001
UPDRS IV C  score 0.6 i  0.8 0.5 i  0.7 0.6 i  0.8 ns
mean i  standard (0-3) (0-2) (0-3)
deviation (range)
Hoehn and Yahr scale 
mean i  standard 
deviation (range)
All 2.9 i  0.7 (1.5-4) 2.7 i  0.6 (2-4) 2.8 i  0.6 
(1.5-4)
ns 2.5 i  0.6 (1.5-4) .041
Female 3.1 ± 0.6 2.6 i  0.5 3.0 i  0.7 ns 2.5 i  0.7 .005
Male 2.6 ± 0.6 2.8 i  0.7 2.6 i  0.5 ns 2.4 ± 0.5 ns
p value
Female versus Male
.009 ns ns ns
Abbreviations: MLIC, motor levodopa-induced complications; ns, nonsignificant; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating 
Scale.
aFisher's exact test, 2 x 2 contingency table, nothing—Mann-W hitney test.
and longer duration of levodopa therapy. These findings except for 
sex d ifferences (probably due to low sample size) are coherent with 
results of previous studies on clinical risk factors of M LIC  (Olanow 
et al., 2013; Scott, Macleod, & Counsell, 2016). No association was 
found between individual BD N F, DAT, and C O M T polymorphisms 
and M LIC  in multinominal logistic regression analysis; meanwhile, 
genotypes combination of AG  B D N F, AG  DAT, and GG C O M T was 
correlated with M LIC  and genotypes combination of GG BD N F, A A  
DAT, and A A  C O M T with lack of M LIC  in PD  patients in O P LS  analy­
sis. O ur results on individual B D N F  Val66M et and C O M T Val158M et 
polym orphism s are in concordance with studies on Israeli and 
A ustra lian/U K PD  patients which showed no association between 
those S N P s and prevalence or time to onset of levodopa-induced 
dyskinesias (Cheshire et al., 2014; Kaplan et al., 2014). However, in 
a single study on PD  patients in the m ajority Caucasians, the allele A 
of the B D N F  Val66M et S N P  (related to decreased protein secretion) 
was associated with higher risk of developing levodopa-induced dys­
kinesias (Foltynie et al., 2009), and futhremore the low -activity allele 
A  of the C O M T Val158M et S N P  was reported to increase the risk 
of levodopa-induced dyskinesias in Dutch PD patients (de Lau et al.,
2012), and to decrease the risk of w earing-off phenomena in Chinese 
PD patients (Wu et al., 2014). The 9-copy allele of 40-p b  V N T R
polym orphism  in DAT gene was found to be a predictor for the occur­
rence of not only dyskinesias but also psychosis in Caucasians (Kaiser 
et al., 2003), while the allele C  of the rs393795 SN P  in that gene 
was reported to extend time to dyskinesias onset in Israeli (Kaplan 
et al., 2014) levodopa-treated PD  patients. No associations were 
found between combined B D N F  Val66M et, C O M T Val158M et, and 
T941G  M A O -A  S N P s and the prevalence or time to onset of levodo­
pa-induced dyskinesias in A u stra lian /U K  PD  patients (Cheshire et al., 
2014). Com bination of B D N F, DAT, and C O M T polym orphism s and 
the occurrence of M LIC  were investigated for the first time.
The e ffe ct of B D N F  on motor function is suggested by the as­
sociation between the V al66M et SN P  and reduced experience-de­
pendent p lasticity of motor cortex (Kleim  et al., 2006) as well as 
impaired synaptic p lastic ity in the nigrostriatal system  (Egan et al.,
2003) which could play a role in the developm ent of M LIC  in PD  pa­
tients. Lower D A T levels in nigrostriatal neurons are associated with 
increased D A  turnover and greater oscillations in synaptic D A  co n ­
centrations in PD  (Sossi et al., 2007). W e hypothesize that allele G of 
rs397595 D A T polym orphism , possibly like allele A  of another S N P — 
rs393795—in this gene (Kaplan et al., 2014), might be related to 
lower D A T level contributing to the developm ent of M LIC . A  poten­
tial link between polym orphism s of C O M T  gene and susceptibility
0.3 i  0.6 ns
(0-2)
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T A  B L E  4  G enotype frequencies of rs6265 B D N F  (Val66M et), rs397595 D A T (SLC6A 3) and rs4680  C O M T  (Val158M et) polym orphism s in 
Parkinson's disease patients with and without motor levodopa-induced com plications
Gene Genotypes
PD patients 
with M LIC 
n (%)
PD patients without 
M LIC
n (%)
X 2 with/ 
without M LIC
p value with/ 
without M LIC O R  (95% CI)
p value with 
versus without 
M LIC
BDN F All GG 11 (26.2%) 13 (38.2%) 11.115/6.788 .001/.009 0.57 (0.22-1.52) .4
AG 30 (71.4%) 21 (61.8%) 1.55 (0.59-4.05) .5
A A 1 (2.4%) 0 (%) -
Female GG 7 (29.2%) 7 (43.8%) 7.218/2.450 .007/.118 0.53 (0.13-1.99) .5
AG 17 (70.8%) 9 (56.2%) 1.89 (0.5-7.09) .5
A A 0 (%) 0 (0%) -
Male GG 4 (22.2%) 6 (33.3%) 4.247/4.500 .039/.034 0.57 (0.13-2.51) .7
AG 13 (72.2%) 12 (66.7%) 1.3 (0.31-5.39) 1.0
A A 1 (5.6%) 0 (0%) -
DAT All A A 18 (42.9%) 20 (58.8%) 2.135/2.2853 .144/.131 0.53 (0.21-1.31) .3
AG 22 (52.3%) 14 (41.2%) 1.57 (0.63-3.91) .5
GG 2 (4.8%) 0 (0%) -
Female A A 11 (45.8%) 9 (56.3%) 1.059/1.2544 .303/.263 0.66 (0.18-2.35) .8
AG 12 (50.0%) 7 (43.8%) 1.29 (0.36-4.58) 1.0
GG 1 (4.2%) 0 (0%) -
Male A A 7 (38.9%) 11 (61.1%) 1.125/1.0488 .289/.306 0.41 (0.11-1.55) .3
AG 10 (55.6%) 7 (38.9%) 1.96 (0.52-7.41) .5
GG 1 (5.5%) 0 (0%) -
COM T All A A 15 (35.7%) 13 (38.2%) 0.656/0.001 .418/.982 0.9 (0.35-2.29) 1.0
AG 18 (42.9%) 16 (47.1%) 0.84 (0.34-2.09) .9
GG 9 (21.4%) 5 (17.7%) 1.58 (0.48-5.26) .6
Female A A 5 (20.8%) 5 (31.3%) 0.174/0.237 .676/.627 0.58 (0.14-2.46) .7
AG 13 (54.2%) 7 (43.7%) 1.52 (0.43-5.43) .8
GG 6 (25.0%) 4 (25.0%) 1 (0.23-4.31) 1.0
Male A A 10 (55.5%) 8 (44.4%) 2.148/0.572 .143/.450 1.56 (0.42-5.82) .7
AG 5 (27.8%) 9 (50.0%) 0.38 (0.1-1.54) .3
GG 3 (16.7%) 1 (5.6%) 3.4 (0.32-36.27) .6
Abbreviations: 95% CI, 95% confidence interval; BDNF, brain-derived neurotrophic factor; COMT, catechol-O-methyltransferase; DAT, dopamine 
transporter; MLIC, motor levodopa-induced complications; OR, odds ratio; PD, Parkinson's disease; x 2, chi-square.
to M LIC  is proposed because of increased risk of M LIC  in PD  pa­
tients on higher cum ulative levodopa dose (Scott et al., 2016) and 
also the probable relationship of high C O M T  activ ity  genotype with 
faster levodopa catabolism  and less stable serum and brain drug 
concentrations leading to higher optimal clin ically levodopa daily 
dose (Bialecka et al., 2008; Lee, Lyoo, Ulamnen, Syvänen, & Rinne, 
2001). It was also found that PD  patients carrying alleles that induce 
both high C O M T  activ ity  and high M A O -A  expression genotypes, 
received higher maximum and daily LE D  (Cheshire et al., 2014). The 
allele G of the C O M T  Val158M et S N P  is related to high a ctiv ity  of 
the enzym e (Lotta et al., 1995). O ur results suggest a synergic e ffect 
of low secretion B D N F, probably low-level D A T and high C O M T  ac­
tiv ity  genotypes on the occurrence of M LIC . Precise mechanisms 
through which B D N F, DAT, and C O M T  polym orphism s may inter­
act which each other and conduct to a phenotype with greater ten­
dency to developing M LIC  require further and w ider investigations.
A lthough the sample in the present study is ethnically hom oge­
nous, a low number of enrolled subjects is a limitation. Larger sample 
sizes are required not only to confirm  our results but also to d istin­
guish groups with different types of M LIC  that may have both com ­
mon and distinct pathom echanism s.
In conclusion , the present stu d y confirm ed the association of 
B D N F  V a l6 6 M e t S N P  w ith the risk of PD  and show ed a potential 
syn e rg ic e ffe ct of B D N F  V a l66M et, rs397595 DAT, and C O M T  
V a l1 5 8 M e t S N P s  on the occurrence of M LIC . T h is  potential g e ­
netic b iom arker m ay help to p red ict w hich PD  patients are more 
placed at risk  of these long-term  adverse e ffe cts  of levodopa 
thera py.
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